Pelthos Therapeutics Initiates Phase 1b/2a Trial of CT2000 Eye Drops for Chronic Ocular Pain in Dry Eye Disease
核心洞察
Pelthos Therapeutics (搜索) has dosed the first patient in a Phase 1b/2a clinical trial evaluating CT2000, a novel NaV1.7 inhibitor eye drop formulation for treating chronic ocular pain associated with dry eye disease.
CT2000 targets the sodium ion-channel NaV1.7 in corneal nerve plexus, offering a potential alternative to current limited therapies including steroids, NSAIDs, and lubricants that have effectiveness or safety limitations.
The adaptive, placebo-controlled trial includes an ascending dose Phase 1 study with acute pain measures followed by a 28-day Phase 2a maximum tolerated dose evaluation, with results anticipated by end of 2026.
Pelthos Therapeutics (搜索) has achieved a significant milestone by dosing the first patient in a Phase 1b/2a clinical trial of CT2000, a novel topical eye drop targeting chronic ocular pain associated with dry eye disease. The study represents the first human evaluation of this NaV1.7 inhibitor formulation, marking a strategic expansion for the commercial-stage biopharmaceutical company into the underserved pain management sector.
Novel Mechanism Targets Corneal Pain Pathways
CT2000 is a specialized ophthalmic formulation of Channel Therapeutics (搜索)' CC8464 compound that specifically targets the sodium ion-channel NaV1.7, a critical component in peripheral nerve pain signal propagation. The therapeutic approach capitalizes on the widespread expression of NaV1.7 channels in the corneal nerve plexus, making it an attractive target for treating ocular pain conditions.
"The successful dosing of the first patient is a meaningful step in advancing Channel's pipeline of eye pain treatments," said Scott Plesha, CEO of Pelthos. "While we remain focused on advancing our commercial-stage programs, the positive results from CT2000 animal efficacy studies suggest that the inhibition of NaV1.7 may have broad applications in treating different pain indications, including areas where new therapeutic options are needed."
Addressing Significant Unmet Medical Need
Current treatment options for eye pain, including steroids, topical non-steroidal anti-inflammatory agents, lubricants, and local anesthetics, face substantial limitations in effectiveness and safety profiles that restrict their duration of use. The chronic ocular pain market represents a substantial opportunity, with global market projections reaching $5.3 billion by 2032.
Eye pain manifests across various conditions including severe dry eye disease, trauma, and surgical procedures. The development of CT2000 specifically addresses moderate to severe dry eye disease patients experiencing chronic ocular pain, a population with limited effective therapeutic alternatives.
Adaptive Trial Design Optimizes Development Strategy
The placebo-controlled Phase 1b/2a clinical trial employs an adaptive design structure beginning with a Phase 1 ascending dose study that incorporates acute ocular pain measures. This initial phase transitions into a Phase 2a maximum tolerated dose study featuring a 28-day dosing period to evaluate both safety and clinical efficacy parameters.
The trial design addresses two distinct pain phenotypes: acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease. This comprehensive approach allows researchers to assess CT2000's therapeutic potential across the spectrum of ocular pain conditions while maintaining rigorous safety monitoring protocols.
Preclinical Foundation Supports Clinical Advancement
Channel Therapeutics (搜索) achieved predefined endpoints in two preclinical animal models of CT2000 eye drop formulations in May 2025, demonstrating efficacy in treating both acute ocular pain and chronic ocular surface pain associated with dry eye disease. These positive preclinical results provided the scientific foundation for advancing the compound into human clinical trials.
The strategic decision to conduct the clinical work through Channel's Australian subsidiary offers operational advantages including established early-phase ophthalmology networks and a regulatory environment conducive to adaptive trial designs. This approach enables efficient proof-of-concept development while managing costs and timelines for the small-cap sponsor.
Market Positioning and Commercial Strategy
For Pelthos Therapeutics (搜索), this trial represents a strategic diversification from its established commercial portfolio of cutaneous infectious disease products. The company's current marketed products include ZELSUVMI (berdazimer) topical gel for Molluscum contagiosum, Xepi (搜索) (ozenoxacin) Cream for impetigo, and Xeglyze (abametapir) for head lice treatment.
The localized delivery approach of CT2000 aims to unlock NaV1.7's therapeutic potential while minimizing systemic exposure risks that have challenged previous systemic NaV1.7 inhibitor programs in pain management. By concentrating drug exposure at the ocular surface where corneal nerve density and accessibility may enable meaningful therapeutic effects, the program seeks to overcome historical limitations of this target class.
Timeline and Development Outlook
Topline results from the Phase 1b/2a trial are anticipated by the end of 2026, providing critical data on CT2000's safety profile and preliminary efficacy signals. The trial's adaptive design allows for real-time optimization of dosing strategies and patient selection criteria based on emerging safety and efficacy data.
The development program's success will depend on demonstrating sustained symptom reduction over the 28-day evaluation period while maintaining an acceptable ocular safety profile, including assessments of corneal staining, epithelial integrity, intraocular pressure, and visual acuity. Patient selection criteria focusing on chronic ocular surface pain phenotypes will be crucial for generating interpretable efficacy signals in this challenging therapeutic area.